Publications by authors named "L Ryom"
Objectives: Tuberculosis (TB) risk after initiation of antiretroviral treatment (ART) is not well described in a European setting, with an average TB incidence of 25/10 in the background population.
Methods: We included all adult persons with HIV starting ART in the RESPOND cohort between 2012 and 2020. TB incidence rates (IR) were assessed for consecutive time intervals post-ART initiation.
Infections in pregnancy are common, and although often not harmful to the woman or her unborn child, some infections may be associated with severe adverse outcomes. Pregnancy causes physiological and immunological adaptations which may make pregnant women more susceptible to infections and at increased risk of more severe illness. Infections in pregnancy represent a challenging area of concern for many specialists and general practitioners.
View Article and Find Full Text PDFBackground: With integrase strand transfer inhibitor (INSTI) use associated with increased body mass index (BMI) and BMI increases associated with higher diabetes mellitus (DM) risk, this study explored the relationship between INSTI/non-INSTI regimens, BMI changes, and DM risk.
Methods: RESPOND participants were included if they had CD4, HIV RNA, and ≥ 2 BMI measurements during follow up. Those with prior DM were excluded.
Article Synopsis
- The study explored the impact of newer antiretroviral drugs (ARVs) on chronic liver enzyme elevation (cLEE) in people with HIV who started ARVs after January 1, 2012.
- Over the follow-up period, 11.3% of participants experienced cLEE, with higher rates observed in the first year but no cumulative effect from ARV use over time.
- Notably, the use of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and tenofovir disoproxil fumarate (TDF) increased the risk of cLEE, while darunavir (DRV) appeared to reduce the risk.